http://purl.org/np/RAymPzHleRaxxoSGl85qjP2e8Xbx6kETXMYV-2rrvg59g#Head
http://purl.org/np/RAymPzHleRaxxoSGl85qjP2e8Xbx6kETXMYV-2rrvg59g
http://www.nanopub.org/nschema#hasAssertion
http://purl.org/np/RAymPzHleRaxxoSGl85qjP2e8Xbx6kETXMYV-2rrvg59g#assertion
http://purl.org/np/RAymPzHleRaxxoSGl85qjP2e8Xbx6kETXMYV-2rrvg59g
http://www.nanopub.org/nschema#hasProvenance
http://purl.org/np/RAymPzHleRaxxoSGl85qjP2e8Xbx6kETXMYV-2rrvg59g#provenance
http://purl.org/np/RAymPzHleRaxxoSGl85qjP2e8Xbx6kETXMYV-2rrvg59g
http://www.nanopub.org/nschema#hasPublicationInfo
http://purl.org/np/RAymPzHleRaxxoSGl85qjP2e8Xbx6kETXMYV-2rrvg59g#pubinfo
http://purl.org/np/RAymPzHleRaxxoSGl85qjP2e8Xbx6kETXMYV-2rrvg59g
http://www.w3.org/1999/02/22-rdf-syntax-ns#type
http://www.nanopub.org/nschema#Nanopublication
http://purl.org/np/RAymPzHleRaxxoSGl85qjP2e8Xbx6kETXMYV-2rrvg59g#assertion
http://purl.obolibrary.org/obo/DOID_437
https://w3id.org/biolink/vocab/category
https://w3id.org/biolink/vocab/Disease
http://purl.org/np/RAymPzHleRaxxoSGl85qjP2e8Xbx6kETXMYV-2rrvg59g#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#object
http://purl.obolibrary.org/obo/DOID_437
http://purl.org/np/RAymPzHleRaxxoSGl85qjP2e8Xbx6kETXMYV-2rrvg59g#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#predicate
https://w3id.org/biolink/vocab/treats
http://purl.org/np/RAymPzHleRaxxoSGl85qjP2e8Xbx6kETXMYV-2rrvg59g#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#subject
https://identifiers.org/drugbank:DB00468
http://purl.org/np/RAymPzHleRaxxoSGl85qjP2e8Xbx6kETXMYV-2rrvg59g#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#type
http://www.w3.org/1999/02/22-rdf-syntax-ns#Statement
http://purl.org/np/RAymPzHleRaxxoSGl85qjP2e8Xbx6kETXMYV-2rrvg59g#association
http://www.w3.org/2000/01/rdf-schema#label
"Quinine sulfate is contraindicated in patients with the following: Prolongation of QT interval ( 4 Glucose-6-phosphate dehydrogenase (G6PD) deficiency ( 4 Myasthenia gravis ( 4 Known hypersensitivity to quinine, mefloquine, or quinidine ( 4 Optic neuritis ( 4 Quinine sulfate is contraindicated in patients with the following: * Prolonged QT interval. One case of a fatal ventricular arrhythmia was reported in an elderly patient with a prolonged QT interval at baseline, who received quinine sulfate intravenously for P. falciparum [see WARNINGS AND PRECAUTIONS ( 5.3 * Glucose-6-phosphate dehydrogenase (G6PD) deficiency. * Hemolysis can occur in patients with G6PD deficiency receiving quinine. * Known hypersensitivity reactions to quinine. * These include, but are not limited to, the following [see WARNINGS AND PRECAUTIONS ( 5.6 * Thrombocytopenia * Idiopathic thrombocytopenia purpura (ITP) and Thrombotic thrombocytopenic purpura (TTP) * Hemolytic uremic syndrome (HUS) * Blackwater fever (acute intravascular hemolysis, hemoglobinuria, and hemoglobinemia) * Known hypersensitivity to mefloquine or quinidine: cross-sensitivity to quinine has been documented [see WARNINGS AND PRECAUTIONS ( 5.6 * Myasthenia gravis. Quinine has neuromuscular blocking activity, and may exacerbate muscle weakness. * Optic neuritis. Quinine may exacerbate active optic neuritis [see ADVERSE REACTIONS ( 6"
http://purl.org/np/RAymPzHleRaxxoSGl85qjP2e8Xbx6kETXMYV-2rrvg59g#association
https://w3id.org/biolink/vocab/provided_by
https://w3id.org/um/NeuroDKG
http://purl.org/np/RAymPzHleRaxxoSGl85qjP2e8Xbx6kETXMYV-2rrvg59g#association
https://w3id.org/biolink/vocab/relation
https://schema.org/MedicalContraindication
https://identifiers.org/drugbank:DB00468
https://w3id.org/biolink/vocab/category
https://w3id.org/biolink/vocab/Drug
http://purl.org/np/RAymPzHleRaxxoSGl85qjP2e8Xbx6kETXMYV-2rrvg59g#provenance
http://purl.org/np/RAymPzHleRaxxoSGl85qjP2e8Xbx6kETXMYV-2rrvg59g#assertion
http://www.w3.org/ns/prov#wasAttributedTo
https://orcid.org/0000-0002-1468-3557
http://purl.org/np/RAymPzHleRaxxoSGl85qjP2e8Xbx6kETXMYV-2rrvg59g#pubinfo
http://purl.org/np/RAymPzHleRaxxoSGl85qjP2e8Xbx6kETXMYV-2rrvg59g#sig
http://purl.org/nanopub/x/hasAlgorithm
RSA
http://purl.org/np/RAymPzHleRaxxoSGl85qjP2e8Xbx6kETXMYV-2rrvg59g#sig
http://purl.org/nanopub/x/hasPublicKey
MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCODwZkXojpEKwk7Ldj2oPPfCstvqrcpgCaTLo235K7ht9C7E1GCkLvUuL2b4VWXJTcZx/hxgDauR8hUeYq/lS6tfTL9yFZsnfl+PWYDyz7vv6N+wJVx2LL8bO6ntCjcOzvW2t2WUeF12Sb6b3I6uOYP0N8iQKts1WasY/yEYKAHQIDAQAB
http://purl.org/np/RAymPzHleRaxxoSGl85qjP2e8Xbx6kETXMYV-2rrvg59g#sig
http://purl.org/nanopub/x/hasSignature
T3N3TGK5kHu+neLOtZXrtOnpSw3grcBqr1rVJrHngOeardHubJl2iz+jiYJ8cgDP9/IiglORHW1fpPFWcjjz+QIwrLDtmxl9ORr30gi+JcjE+QHuVh/QNeZCFlfK/GrE32Gig9oSpEvtA1qVESS+9oyxeuts3EJg0u9U+qdz2KY=
http://purl.org/np/RAymPzHleRaxxoSGl85qjP2e8Xbx6kETXMYV-2rrvg59g#sig
http://purl.org/nanopub/x/hasSignatureTarget
http://purl.org/np/RAymPzHleRaxxoSGl85qjP2e8Xbx6kETXMYV-2rrvg59g
http://purl.org/np/RAymPzHleRaxxoSGl85qjP2e8Xbx6kETXMYV-2rrvg59g
http://purl.org/dc/terms/created
2021-08-23T18:44:18.224+02:00
http://purl.org/np/RAymPzHleRaxxoSGl85qjP2e8Xbx6kETXMYV-2rrvg59g
http://purl.org/dc/terms/creator
https://orcid.org/0000-0002-1468-3557
http://purl.org/np/RAymPzHleRaxxoSGl85qjP2e8Xbx6kETXMYV-2rrvg59g
https://w3id.org/np/o/ntemplate/wasCreatedFromProvenanceTemplate
http://purl.org/np/RANwQa4ICWS5SOjw7gp99nBpXBasapwtZF1fIM3H2gYTM
http://purl.org/np/RAymPzHleRaxxoSGl85qjP2e8Xbx6kETXMYV-2rrvg59g
https://w3id.org/np/o/ntemplate/wasCreatedFromPubinfoTemplate
http://purl.org/np/RAA2MfqdBCzmz9yVWjKLXNbyfBNcwsMmOqcNUxkk1maIM
http://purl.org/np/RAymPzHleRaxxoSGl85qjP2e8Xbx6kETXMYV-2rrvg59g
https://w3id.org/np/o/ntemplate/wasCreatedFromTemplate
http://purl.org/np/RAhNHZw6Urw_Mccs4qy6Ws3C9CRuaHpQx8AwuApbWkqnY